CN105037195A - 乙酰谷酰胺及其注射液与制备方法 - Google Patents
乙酰谷酰胺及其注射液与制备方法 Download PDFInfo
- Publication number
- CN105037195A CN105037195A CN201510362529.2A CN201510362529A CN105037195A CN 105037195 A CN105037195 A CN 105037195A CN 201510362529 A CN201510362529 A CN 201510362529A CN 105037195 A CN105037195 A CN 105037195A
- Authority
- CN
- China
- Prior art keywords
- preparation
- aceglutamide
- injection
- sodium
- sodium hydroxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005488 aceglutamide Drugs 0.000 title claims abstract description 87
- KSMRODHGGIIXDV-YFKPBYRVSA-N N-acetyl-L-glutamine Chemical compound CC(=O)N[C@H](C(O)=O)CCC(N)=O KSMRODHGGIIXDV-YFKPBYRVSA-N 0.000 title claims abstract description 72
- 238000002360 preparation method Methods 0.000 title claims abstract description 53
- 238000002347 injection Methods 0.000 title claims abstract description 37
- 239000007924 injection Substances 0.000 title claims abstract description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 38
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000012346 acetyl chloride Substances 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 110
- 239000000243 solution Substances 0.000 claims description 43
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 26
- 239000001632 sodium acetate Substances 0.000 claims description 26
- 229960004249 sodium acetate Drugs 0.000 claims description 26
- 235000017281 sodium acetate Nutrition 0.000 claims description 26
- 239000007788 liquid Substances 0.000 claims description 22
- 239000008215 water for injection Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 16
- -1 aceglutamide compound Chemical class 0.000 claims description 16
- 239000003002 pH adjusting agent Substances 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 15
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 claims description 13
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 9
- 239000011259 mixed solution Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 6
- 239000003610 charcoal Substances 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 229910017488 Cu K Inorganic materials 0.000 claims description 4
- 229910017541 Cu-K Inorganic materials 0.000 claims description 4
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 4
- 230000005260 alpha ray Effects 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 4
- 229940105082 medicinal charcoal Drugs 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 238000009413 insulation Methods 0.000 claims description 3
- 239000003607 modifier Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 abstract description 18
- 239000013078 crystal Substances 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 2
- 230000036632 reaction speed Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 239000000126 substance Substances 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 206010010075 Coma hepatic Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000005261 decarburization Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510362529.2A CN105037195B (zh) | 2015-06-26 | 2015-06-26 | 乙酰谷酰胺及其注射液与制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510362529.2A CN105037195B (zh) | 2015-06-26 | 2015-06-26 | 乙酰谷酰胺及其注射液与制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105037195A true CN105037195A (zh) | 2015-11-11 |
CN105037195B CN105037195B (zh) | 2018-04-13 |
Family
ID=54444241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510362529.2A Active CN105037195B (zh) | 2015-06-26 | 2015-06-26 | 乙酰谷酰胺及其注射液与制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105037195B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107582521A (zh) * | 2017-09-27 | 2018-01-16 | 江西省子轩科技有限公司 | 一种稳定性好的乙酰谷酰胺注射液及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101434559A (zh) * | 2008-12-12 | 2009-05-20 | 上海朝晖药业有限公司 | 乙酰谷酰胺的制备方法 |
CN102018668A (zh) * | 2010-12-08 | 2011-04-20 | 上海朝晖药业有限公司 | 一种乙酰谷酰胺注射液的制备方法 |
CN102276496A (zh) * | 2011-07-28 | 2011-12-14 | 周晓东 | 乙酰谷酰胺化合物及其药物组合物 |
CN102358721A (zh) * | 2011-08-26 | 2012-02-22 | 贺金凤 | 一种更为稳定的乙酰谷酰胺化合物及其药物组合物 |
CN103012192A (zh) * | 2013-01-10 | 2013-04-03 | 黄明芳 | 一种新型乙酰谷酰胺化合物及其药物组合物 |
CN104140378A (zh) * | 2014-05-22 | 2014-11-12 | 浙江磐谷药源有限公司 | 乙酰谷酰胺特种超细粉体冻干制剂及其制备方法 |
-
2015
- 2015-06-26 CN CN201510362529.2A patent/CN105037195B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101434559A (zh) * | 2008-12-12 | 2009-05-20 | 上海朝晖药业有限公司 | 乙酰谷酰胺的制备方法 |
CN102018668A (zh) * | 2010-12-08 | 2011-04-20 | 上海朝晖药业有限公司 | 一种乙酰谷酰胺注射液的制备方法 |
CN102276496A (zh) * | 2011-07-28 | 2011-12-14 | 周晓东 | 乙酰谷酰胺化合物及其药物组合物 |
CN102358721A (zh) * | 2011-08-26 | 2012-02-22 | 贺金凤 | 一种更为稳定的乙酰谷酰胺化合物及其药物组合物 |
CN103012192A (zh) * | 2013-01-10 | 2013-04-03 | 黄明芳 | 一种新型乙酰谷酰胺化合物及其药物组合物 |
CN104140378A (zh) * | 2014-05-22 | 2014-11-12 | 浙江磐谷药源有限公司 | 乙酰谷酰胺特种超细粉体冻干制剂及其制备方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107582521A (zh) * | 2017-09-27 | 2018-01-16 | 江西省子轩科技有限公司 | 一种稳定性好的乙酰谷酰胺注射液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105037195B (zh) | 2018-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106822175A (zh) | 一种碳酸氢钠林格注射液及其制备方法 | |
CN106606476A (zh) | 一种布洛芬混悬滴剂及其制备方法 | |
CN110507616A (zh) | 一种盐酸金霉素可溶性粉及其制备方法 | |
CN105037195A (zh) | 乙酰谷酰胺及其注射液与制备方法 | |
CN102600070B (zh) | 环磷腺苷葡胺组合物注射液及其制备方法 | |
CN103159817A (zh) | 一种琥珀酸甲泼尼龙的制备方法 | |
CN109820827A (zh) | 一种注射用阿扎胞苷冻干粉针及其制备方法 | |
CN110251461B (zh) | 复合维生素b注射液及其制备方法 | |
CN109620804B (zh) | 一种注射用头孢曲松钠粉针制剂及其制备方法 | |
CN102846561A (zh) | 一种供注射用的奥扎格雷钠药物组合物 | |
CN107595769A (zh) | 一种磺达肝癸钠注射液组合物的制备方法 | |
CN104906127B (zh) | 一种有效碘含量稳定性增强的聚维酮碘复方制剂及其制备方法 | |
CN102258507A (zh) | 含有布洛芬的药物组合物及其制备方法和应用 | |
CN106074366B (zh) | 治疗脑外伤及脑手术后意识障碍的注射液及其制备方法 | |
CN103751104A (zh) | 依达拉奉注射液及其制备方法 | |
CN102949413B (zh) | 一种转化糖电解质注射液的制备方法 | |
CN104906036A (zh) | 阿魏酸左旋咪唑注射液的制备方法 | |
CN106188177A (zh) | 一种阿奇霉素化合物的制备方法及其药物制剂 | |
CN1099871C (zh) | 双甘注射液及其制备方法 | |
CN103877015B (zh) | 一种盐酸溴己新葡萄糖注射液的制备方法 | |
CN116570560A (zh) | 一种地塞米松磷酸钠注射液及其制备方法 | |
CN109172622A (zh) | 一种治疗中耳炎的药液及其制备方法 | |
CN104557585A (zh) | 盐酸丁卡因晶体、含有盐酸丁卡因的组合物、及制备方法 | |
DE2036678A1 (de) | Antibiotika | |
CN103705933A (zh) | 奥卡西平药物组合物及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Acetylglutamine and its injection and preparation method Effective date of registration: 20210730 Granted publication date: 20180413 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021430000029 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211014 Granted publication date: 20180413 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021430000029 |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: No.8 Kangpu Avenue, high tech Industrial Park, Hanshou County, Changde City, Hunan Province, 415900 Patentee after: KAMP PHARMACEUTICALS Co.,Ltd. Address before: 12 / F, building B, Lugu information port, 658 Lugu Avenue, high tech Zone, Changsha City, Hunan Province, 410205 Patentee before: KAMP PHARMACEUTICALS Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Acetylglutamine and its injection and preparation method Effective date of registration: 20211028 Granted publication date: 20180413 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021980011259 |